HUE031661T2 - Szerotonin receptor agonisták kombinációi mozgási rendellenességek kezelésére - Google Patents

Szerotonin receptor agonisták kombinációi mozgási rendellenességek kezelésére Download PDF

Info

Publication number
HUE031661T2
HUE031661T2 HUE11776071A HUE11776071A HUE031661T2 HU E031661 T2 HUE031661 T2 HU E031661T2 HU E11776071 A HUE11776071 A HU E11776071A HU E11776071 A HUE11776071 A HU E11776071A HU E031661 T2 HUE031661 T2 HU E031661T2
Authority
HU
Hungary
Prior art keywords
day
combination
receptor
agonist
buspirone
Prior art date
Application number
HUE11776071A
Other languages
English (en)
Inventor
John Bondo Hansen
Mikael S Thomsen
Original Assignee
Contera Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contera Pharma Aps filed Critical Contera Pharma Aps
Publication of HUE031661T2 publication Critical patent/HUE031661T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (3)

  1. SZEROTÜNlN RECEPTOR âiMliSTÎK KOMBINÂCÈÔI MOZGÁSI RENDE!.tENESSÉCSER KEZELÉSÉRE ' 'OypiastoH Egy gyAgysttensnaet; kèsxltaëoy vagy résaagytagekböi àüô Kit. nroety s kívaíkeataet tsnalrosaaa ktgnââbfc egy vagyaiét, ata: a;·: «mFtta vegyuta h-HÏ- D. b-H'ft B àa S-H — F fooeptor ag- na.;» vagy annak g> og y tve fás,: ín : &amp; g aifogadhfc·«) vannas-eka ota ai »'tata; uxtvatm ogs a ma t vagy gyae> x- >aitaasg «tfopaohata ata na» aka >'» ahol sa. amiseit vagyis«· vagy Ktamgyaégekbol OHE kétaattatatmav tovébM epy » Hl Λ m apter agon-Hât vagy an-v^ gyégy&amp;ïôfée-ie^eg aiiogadfcmâ akémtaxékát, mosdás? iPSitatsnassége fc*s*È»s%. stageltabsa vagy emtatèsera sósán történő alkatinak a i. Aa ·. :ga·:ypont xtentö aikalm&amp;mndögyipasafAszÄifednsèny vagy ratargységekíta álló kik »hoi a vegyek?; nagyabb sttartaesp! «s/vagy rt?o«t:noiáktl válást bátásossággsi modsekettlk at; δ-H'i'l D mceptof s setae- ' a. 5 E í ' p ne a. ·Ήη s»·· amtano< ta; est
  2. 3. Az öío.í:ö igénypontok bâtroelylke szennl. alkssloiaxand» gyôgyattaèsata Mstamény vagy íAssksgysAgakbat állá tok ahol a yagyëta a kővetkező cstípotlbó; kerül kHátaszlásm: zolnktnptáit. sx«ntatnpián. rtzaínptöo. avetöptán, airaatnptáo, tmvatbptán ás éístn&amp;lán vagy ázok gytKtvszetöszetileg o;Kíga<lhaté s^wsaiakat. A< A.; előző igénypontok bánnelyika szenet alkakna?anstö gyógyszerészeti kstantaéoy vagy rtttaegyeégekta; atte kit. ata> az 5-HTIA agomsta a kivetkező ^sC'PtmÄI®ii!iferälä^^«a: tastyron. ainesplron, EHottaK-n pennon. tpsapiron, rtaosplnvn, !en<töapv'on. beíiradob mpmgStn. paiozotety üt.eoto.itaa'n. Ivtannoín taanxn-so és ssnzotan vagy erők r : yèem re ; észtateg oltaptdbatö származéka* !|. Az lelözo sippypoAlta Eánnelylke ereont !á|k^ÉtözAod!f oyogyazeotözek kéezamèny vagy részegységekből álé kit. tstta .?·. vegyest a zéltatbpilta vagy annak pyégpàsîtsistji^rktOgaEÀsté s i \ ta? nf> \ ^ uv' ' ' < ! "> í «. V* “ ^ s' V*' vítacj «sogadnstô ézAmigzAka: Aj előző sgénypan-n;!· ttatanyoe szerint alkalmazandó Ityógytaenitata készítmény vagy bésaegyslgaköél álla lét, aboi a tmmèk Pdagsjlé&amp;lm EpiEííöS itpgínap ^ds^feaPkiÄft^liSMi'Öi^ö. '' F X en\'50 'in >. 'â^ H ' i "ν' '8). t U 'btno^Xi a va 0 H ί n&amp;p mint pèitiktil 0,5-1(10 n'ignxsp, nőn; pèidEal 0.íj~30 mg/nap oàaieokbsn kari.il jôf. ?. Ay ek'laô ilgëàyjAInOk !iâôp|lyskàl RkéRpI::: nlkisinlarandô gyôpysyecésrek kèSiiiirnèny vagy fèazagysè^kbôt :i!feà!L amsly ipyábtsá agy vsgyi i§feb:agyéb aktlvlEasagtayAFtaiiältnssi:. 8 A 7. Igôiiygnnt erermt aikainexaota gyô§ysa;xé;tvnt: kaeaAniènv vágy ta&amp;?eyy%e§eKtx5; ëüb kst, aitoi ax en:lItat agy vagy több egyéb aknv ötexetavn a kovískaió nenpobból - ·ξ-Κ;! 'Avpinafplsici A rilnat'iAoy inetioî; a dopssniln koncnrisràt.niiàt n.ovstö agantsek: a Rarkfneon-kór v^^^iaseíe naeanait ánansek. ;Ag.-nín;n t.-DOPA dopvaavn-ronoptof agon isták vagy niótAnak g>ogy\re;èkëtatng abogndhaíé SjO'n^.nk.í, of tadvta .·' inï-hta«·» ·.,Oki;' ikotokoi s'1 'ta A tovuta, · ;ν n>tv, ^ Nn\t '*· î'j .not· t' askpastat; antagonsatâk: MÀO-S s'ibkíltanak. zmmimïu mcsutatofek; k arsp· .-t'D'esd tv-'.aotor {sarorns-anano vojsav} ptodulétorok. oouronélis kâà-jiocsaîornâk modutéioss is :|ÍíiismáS^öípte mobySteîk,
  3. 9. A t. és 8 igéoypootok fcáweiyska szedni aikai;sa.sati00 gyégpssésssaS; MsPioiipy vagy it.... ,g\ \*\" < ' X ( V ^y ' t ' a*in>v' N\ N y a:-: S-HT1A rseoptof agonists öosblron vagy gyAgya^afSSzebiog sifvpsinski ssäoossSks, és «egy vagy Soha egyéb asdiv öss2fessvb -¾ róveiksaikeí fogiap rostában í. DOS’A vagy qyógvsasjrószqfifeq ekog.sqosx': ssánnazSka es-vagY agy dsHArt>oP«-ií>hsblío« éo-vagy GGMT-*ohshttof !|ï A 'à tgaayiüvs ss-iém aikainxi -smk> pyx^soxsès/et: k'íszénvezy vagy okzzeqyspgaknö! iád kp, and a aAksrtekSáss-eki ksmklops vagy oonsseraPI én/vagy ahoi a ΟΟΜΤ-ΡνΡΡο:· sóik apón vagy oniaknpon. 11. A.z «iczd :génypomok bSmxéyike aaerlnt sSkaíme:.nsrtPe gyagyxKqrsS*éts készítmény vagy ré; .'«gy îégakixiâ aüó ka, ahoi a mozgási fondaiiaoeaság a következő os.-yooitbói kévéi kt\'áies:díkpa mopvásozoh vagy csökkstn sisagtikus doppmirssamtekKo; kaposoiato·* mozgási regéaiiohassêg. Hnrkínsonéor; Padoson-kórhoz 1érs»uto mozgási msdeiianesséoak. botaertvo a braérkistéssák ékioésiai és étsaki-íéíiék L-DCé-A által mdo® dssakinéshk tSAk'v iis£kihé:2:a és skaéga. :1¾ As eiézé :qényponto\ hérnuyiyike szeoré alkaiOsazando ^yógy82ems<s«t« késsimsèny ÿéfy Ps-egysäporbd âiio k« ahoi a mozgás; rendePoespég a koy«:kezô csoportból kard kiválasztásig: atassa, dlszioiaa. essssodéks homo- HiaPagtoo-kbr. miokiómssa. Pált-szindróma, rot«ßft«*S2tdöföm&amp;. Wlhon-kof, chorea, bkedodo vosopivkor avtigkvaa téh&amp;&amp;fKj>O<tva, szpassbkostonmoiiisz. qeoioapazmbé is slyaa SKíkgás: r*poaSí«>nesst«qek. amelyek oka :d<opai;és betegség. genekke; dsszfonlssÄ vagy .« ha o á 11 :> g arsg i ; or · ok fedőzásas vagy dBzfvnkdója. :|fi. Aü «!δ*ί· igénypontok hénneiyiko szánni aikslmsgaodo gyôg>\s£ô«:s.àel! késüftmérty vagy: iêszegysegekzd àtip id séd a mozgás; 'eodetisnessègét gyógyszeres ietáp:« okossá vagy szzál kspcsoihme, haieédve s kévatkázéket: neueúlsoiikes qyégysssi'ok. aakg-ssioSotikvosok, asl:da|>!'fesssé0sí>k.: sneoroatkns gyógyszerek vagy gyogyxs-ssok elvonása okozza vagy azzal· kapcsolat?;, Mléebva: a képtkéKl^éií opbídok. borban ni;tok. kpkáih, áaoyogiasapinok, : síkohpi és samfatamín. éí,: :Íix-1:úvíq|pypqolik:feéímo^yl8é SséÍiia^kiÍp1Ís:prslégyigyssofisisíSfeéss:8rPÍoy;vigy::réssqgpÍgekPÍt: : álló kit, I6bb :agÿ|à;:^ aaagoiásán:; opyszarps. agy-irtási: kovákká: vagy kiioo ks-oiá sor sg aoritos gyógysí.ía="Ss?.ftii késssotonypai vagy íéssagységstkioi aüo kabéi. i§i gyqqyssr>fàasaii réss arsáoy vagv tasssgységekív r m kll alkaknosáss, «>r«iy 3 k.>votke:>Okas iogiaija magsoars: ííív. Sóéi t g> .«χρ. i' -.K a< a ,»q χ^ν κ n ' ’ ;t Ή Vv.'h U,u >. n ) sía vsov aooak gyágyssiV'asssSkia aifagviP sad sy.SaxsrtPa ahoi as aasiîaS vaayuía; agy íriptáp vagy yy-jgyajefas2avieq -iiogaqo-s'b S£anApsaS:;;, fes ahoi az amtitak vagyüss vagy fóssagységakixü Süd héasits îaikév'-tz iovébbé egy Î--H î'i A rasepfót·ag-wslai vagy ásnák qÿi::i¥'sÂ'-'!'és:ïiîbtag eikigaíihato szartnazèsà·, és inoz;gàs: ri;oîkài<::nasstkp;i. kososéi.:* ioogekikc** vagsy opÿi^éséi® alkatot a^^ndé
HUE11776071A 2010-10-15 2011-10-13 Szerotonin receptor agonisták kombinációi mozgási rendellenességek kezelésére HUE031661T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39354510P 2010-10-15 2010-10-15
DKPA201070441 2010-10-15
US201161491945P 2011-06-01 2011-06-01

Publications (1)

Publication Number Publication Date
HUE031661T2 true HUE031661T2 (hu) 2017-07-28

Family

ID=44883032

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11776071A HUE031661T2 (hu) 2010-10-15 2011-10-13 Szerotonin receptor agonisták kombinációi mozgási rendellenességek kezelésére

Country Status (22)

Country Link
US (2) US9186359B2 (hu)
EP (1) EP2627328B1 (hu)
JP (1) JP5907975B2 (hu)
KR (1) KR101825972B1 (hu)
CN (2) CN105193809B (hu)
AU (1) AU2011316225B2 (hu)
BR (1) BR112013009004B1 (hu)
CA (1) CA2813648C (hu)
CY (1) CY1118314T1 (hu)
DK (1) DK2627328T3 (hu)
ES (1) ES2602973T3 (hu)
HR (1) HRP20161402T1 (hu)
HU (1) HUE031661T2 (hu)
IL (1) IL225758A (hu)
LT (1) LT2627328T (hu)
MX (1) MX353625B (hu)
PL (1) PL2627328T3 (hu)
PT (1) PT2627328T (hu)
RS (1) RS55332B1 (hu)
RU (1) RU2611376C2 (hu)
SI (1) SI2627328T1 (hu)
WO (1) WO2012048710A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714040A1 (en) * 2011-06-01 2014-04-09 Concit Pharma ApS Combinations of serotonin receptor agonists for treatment of movement disorders
NZ700474A (en) 2012-04-18 2016-10-28 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
MX2014015266A (es) * 2012-06-11 2015-06-23 Psychogenics Inc Tratamiento de efectos secundarios de trastorno motriz y del movimiento asociados con tratamientos de enfermedad de parkinson.
EP3160464B1 (en) * 2014-06-26 2018-07-18 Contera Pharma APS 6-hydroxybuspirone for use in the treatment of movement disorders
CN106456622B (zh) * 2014-07-09 2020-05-19 皮埃尔法布雷医药公司 用贝非拉醇治疗运动障碍的方法
WO2016210431A1 (en) * 2015-06-26 2016-12-29 Wright State University Method of treating sepsis-induced myopathy
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
CN109689036A (zh) 2016-07-11 2019-04-26 康特拉医药公司 用于治疗早晨运动不能的脉冲药物输送系统
EP3897641B1 (en) 2018-12-20 2023-11-15 Contera Pharma A/S Treatment of movement disorders
WO2021127391A1 (en) * 2019-12-20 2021-06-24 The Jackson Laboratory Molecular targets for addiction
CN112931397B (zh) * 2021-01-25 2024-02-27 江南大学 一种帕金森病动物模型的构建方法
CN114712365B (zh) * 2022-06-07 2022-08-23 山东绿叶制药有限公司 Trk抑制剂在制备治疗迟发性运动障碍药物中的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4182763A (en) 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4777173A (en) 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
US5185329A (en) 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
US6432956B1 (en) 1990-02-12 2002-08-13 William C. Dement Method for treatment of sleep apneas
IL114690A (en) 1990-06-07 1997-02-18 Wellcome Found Antimigraine oxazolidinone substituted indole derivatives
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9209882D0 (en) 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
US5484788A (en) 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5637314A (en) 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US6150365A (en) 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
GB9928578D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
ATE374192T1 (de) 2000-11-29 2007-10-15 Lilly Co Eli 1-(2-m-methansulfonamidophenylethyl)-4-(m- trifluoromethylphenyl)piperazine und ihre akzeptablen pharmazeutischen salze und solvate und ihre verwendung zur behandlung von inkontinenz
WO2002053139A2 (en) 2001-01-05 2002-07-11 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
MXPA04002304A (es) * 2001-09-12 2004-06-29 Merck Patent Gmbh Uso de aminometil cromanos sustituidos en el tratamiento de trastornos de movimiento.
DE10353657A1 (de) 2003-11-17 2005-06-23 Merck Patent Gmbh Indolderivate
EP1711493A2 (en) 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
WO2006027681A1 (en) 2004-09-07 2006-03-16 Pfizer Limited Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
CA2654557A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and l-dopa
US20080227813A1 (en) * 2006-09-26 2008-09-18 Jack Raymond Barber Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
WO2008047839A1 (fr) * 2006-10-19 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. Agoniste du récepteur de la 5-ht1a
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PREPARING RAPID DISAGGREGATION FORMULATION FOR ORAL ADMINISTRATION AND APPARATUS FOR PREPARING AND PACKAGING THEREFOR
EP2317996A1 (en) 2008-06-24 2011-05-11 Anders Björklund Eltoprazine for suppression of l-dopa induced dyskinesias
WO2010044736A1 (en) 2008-10-14 2010-04-22 Mcneil Ab Multi portion intra-oral dosage form and use thereof
GEP20146013B (en) 2009-01-23 2014-01-27 Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It Controlled release pharmaceutical or food formulation and method of preparation thereof
EP2515654A4 (en) 2009-12-23 2013-04-24 Map Pharmaceuticals Inc NEW ERGOLINANALOGA
EP2714040A1 (en) * 2011-06-01 2014-04-09 Concit Pharma ApS Combinations of serotonin receptor agonists for treatment of movement disorders

Also Published As

Publication number Publication date
WO2012048710A1 (en) 2012-04-19
IL225758A (en) 2017-03-30
CA2813648A1 (en) 2012-04-19
CN105193809B (zh) 2019-07-16
AU2011316225A1 (en) 2013-04-18
HRP20161402T1 (hr) 2016-12-30
MX353625B (es) 2018-01-22
US20130252965A1 (en) 2013-09-26
LT2627328T (lt) 2016-11-25
SI2627328T1 (sl) 2017-01-31
BR112013009004A8 (pt) 2017-12-26
DK2627328T3 (en) 2016-12-12
US20160058762A1 (en) 2016-03-03
EP2627328B1 (en) 2016-09-14
JP5907975B2 (ja) 2016-04-26
RU2611376C2 (ru) 2017-02-21
CN103402514A (zh) 2013-11-20
CA2813648C (en) 2019-06-25
MX2013004067A (es) 2013-07-29
PT2627328T (pt) 2016-11-23
CY1118314T1 (el) 2017-06-28
AU2011316225B2 (en) 2016-05-19
ES2602973T3 (es) 2017-02-23
IL225758A0 (en) 2013-06-27
KR20130101545A (ko) 2013-09-13
KR101825972B1 (ko) 2018-02-06
BR112013009004A2 (pt) 2016-07-05
US10632116B2 (en) 2020-04-28
PL2627328T3 (pl) 2017-03-31
RU2013120481A (ru) 2014-11-20
US9186359B2 (en) 2015-11-17
CN105193809A (zh) 2015-12-30
EP2627328A1 (en) 2013-08-21
RS55332B1 (sr) 2017-03-31
CN103402514B (zh) 2016-01-13
BR112013009004B1 (pt) 2022-05-10
JP2013539767A (ja) 2013-10-28

Similar Documents

Publication Publication Date Title
US10632116B2 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
US20140243350A1 (en) Use of serotonin receptor agonists for treatment of movement disorders
EP3897641B1 (en) Treatment of movement disorders
US20140221385A1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
KR102527805B1 (ko) 부스피론 대사물의 용도
US11191758B2 (en) Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors